Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Pz-1 |
Synonyms | |
Therapy Description |
Pz-1 is a small molecule inhibitor with activity against Ret and Kdr (VEGFR2), as well as NTRK1/2/3, which may result in tumor growth inhibition (PMID: 26126987, PMID: 34373541). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Pz-1 | RET Inhibitor 53 Trk Receptor Inhibitor (Pan) 32 VEGFR2 Inhibitor 37 | Pz-1 is a small molecule inhibitor with activity against Ret and Kdr (VEGFR2), as well as NTRK1/2/3, which may result in tumor growth inhibition (PMID: 26126987, PMID: 34373541). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET V804L | Advanced Solid Tumor | predicted - sensitive | Pz-1 | Preclinical | Actionable | In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET V804L (PMID: 26126987). | 26126987 |
RET C634R | Advanced Solid Tumor | sensitive | Pz-1 | Preclinical - Cell culture | Actionable | In a preclinical study, Pz-1 treatment inhibited Ret phosphorylation and growth of transformed cells expressing RET C634R in culture (PMID: 34373541). | 34373541 |
RET C634R | Advanced Solid Tumor | sensitive | Pz-1 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Pz-1 inhibited Ret signaling in transformed cells over expressing RET C634R and inhibited tumor growth in cell line xenografts models (PMID: 26126987). | 26126987 |
RET M918T | medullary thyroid carcinoma | sensitive | Pz-1 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Pz-1 treatment inhibited downstream signaling and growth of a medullary thyroid carcinoma cell line harboring RET M918T in culture, and inhibited tumor growth in cell line xenograft models (PMID: 34373541). | 34373541 |
RET C634W | medullary thyroid carcinoma | sensitive | Pz-1 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Pz-1 treatment inhibited downstream signaling and cell growth of a medullary thyroid carcinoma cell line harboring RET C634W in culture, and inhibited tumor growth in cell line xenograft models (PMID: 34373541). | 34373541 |
HRAS G12V | Advanced Solid Tumor | sensitive | Pz-1 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Pz-1 reduced tumor growth in xenograft models of transformed cells over expressing HRAS G12V in a dose-dependent manner (PMID: 26126987). | 26126987 |
RET M918T | Advanced Solid Tumor | sensitive | Pz-1 | Preclinical - Cell culture | Actionable | In a preclinical study, Pz-1 treatment inhibited Ret phosphorylation and growth of transformed cells expressing RET M918T in culture (PMID: 34373541). | 34373541 |
RET M918T | Advanced Solid Tumor | sensitive | Pz-1 | Preclinical | Actionable | In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET M918T (PMID: 26126987). | 26126987 |
RET V804M | Advanced Solid Tumor | predicted - sensitive | Pz-1 | Preclinical | Actionable | In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET V804M (PMID: 26126987). | 26126987 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|